183 related articles for article (PubMed ID: 11569230)
1. [Changes in prostate-specific antigen in casodex (bicalutamide) monotherapy in a dose 150 mg/day given to patients with locally advanced and/or advanced prostatic cancer].
Kariakin OB; Sviridova TV; Tsodikova LB; Grishin GN; Sergeeva TN; Perekhrest MA; Donichkina EA
Urologiia; 2001; (4):26-9. PubMed ID: 11569230
[TBL] [Abstract][Full Text] [Related]
2. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration.
Tyrrell CJ; Iversen P; Tammela T; Anderson J; Björk T; Kaisary AV; Morris T
BJU Int; 2006 Sep; 98(3):563-72. PubMed ID: 16771791
[TBL] [Abstract][Full Text] [Related]
3. [Preliminary results of casodex use in patients with hormone-resistant cancer of the prostate].
Matveev BP; Bukharkin BV
Urologiia; 2001; (6):20-1. PubMed ID: 11785074
[No Abstract] [Full Text] [Related]
4. Pathological changes of high-grade prostatic intraepithelial neoplasia and prostate cancer after monotherapy with bicalutamide 150 mg.
Scattoni V; Montironi R; Mazzucchelli R; Freschi M; Nava L; Losa A; Terrone C; Scarpa RM; Montorsi F; Pappagallo G; Rigatti P
BJU Int; 2006 Jul; 98(1):54-8. PubMed ID: 16831143
[TBL] [Abstract][Full Text] [Related]
5. Update of monotherapy trials with the new anti-androgen, Casodex (ICI 176,334). International Casodex Investigators.
Iversen P
Eur Urol; 1994; 26 Suppl 1():5-9. PubMed ID: 7737258
[TBL] [Abstract][Full Text] [Related]
6. Is the efficacy of hormonal therapy affected by lymph node status? data from the bicalutamide (Casodex) Early Prostate Cancer program.
Iversen P; Wirth MP; See WA; McLeod DG; Klimberg I; Gleason D; Chodak G; Montie J; Tyrrell C; Wallace DM; Delaere KP; Lundmo P; Tammela TL; Johansson JE; Morris T; Carroll K;
Urology; 2004 May; 63(5):928-33. PubMed ID: 15134983
[TBL] [Abstract][Full Text] [Related]
7. [Monotherapy with casodex at a dose of 150 mg--a new method of hormonal treatment of disseminated prostatic cancer].
Rusakov IG; Alekseev BIa
Urologiia; 2002; (5):23-6. PubMed ID: 12402771
[No Abstract] [Full Text] [Related]
8. Prostate-specific antigen half-life and pretreatment prostate-specific antigen: crucial predictors for prostate-specific antigen trend in delayed-combined androgen blockade therapy.
Soga N; Onishi T; Arima K; Sugimura Y
Int J Urol; 2007 Mar; 14(3):192-6; discussion 197. PubMed ID: 17430253
[TBL] [Abstract][Full Text] [Related]
9. [Adjuvant hormone therapy in prostatic cancer: after treatment with curative intent. The viewpoint of the urologist].
Martorana G
Recenti Prog Med; 2002 Mar; 93(3):179-82. PubMed ID: 11942170
[No Abstract] [Full Text] [Related]
10. Salvage therapy with bicalutamide 150 mg in nonmetastatic castration-resistant prostate cancer.
Lodde M; Lacombe L; Fradet Y
Urology; 2010 Nov; 76(5):1189-93. PubMed ID: 20303155
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcomes of androgen deprivation as the sole therapy for localized and locally advanced prostate cancer.
Janoff DM; Peterson C; Mongoue-Tchokote S; Peters L; Beer TM; Wersinger EM; Mori M; Garzotto M
BJU Int; 2005 Sep; 96(4):503-7. PubMed ID: 16104900
[TBL] [Abstract][Full Text] [Related]
12. Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design.
Sartor O; Gomella LG; Gagnier P; Melich K; Dann R
Can J Urol; 2009 Oct; 16(5):4806-12. PubMed ID: 19796455
[TBL] [Abstract][Full Text] [Related]
13. [Clinical early phase II study of bicalutamide (Casodex) in patients with prostatic cancer].
Kotake T; Usami M; Isaka S; Shimazaki J; Nakano E; Okuyama A; Okajima E; Kanetake H; Saitoh Y; Kumamoto Y; Orikasa S; Sakata Y; Hosaka M; Akaza H; Koiso K; Honma Y; Aso Y; Oishi K; Yoshida O; Naitoh S; Kumazawa J; Koyanagi T; Yachiku S; Shiraiwa Y; Tsukagoshi S
Hinyokika Kiyo; 1996 Feb; 42(2):157-68. PubMed ID: 8712092
[TBL] [Abstract][Full Text] [Related]
14. [Efficacy of bicalutamide in adjuvant treatment of prostatic carcinoma after primary therapy with curative aim. The viewpoint of the surgeon].
Rigatti P; Scattoni V
Recenti Prog Med; 2002 Mar; 93(3):183-5. PubMed ID: 11942171
[No Abstract] [Full Text] [Related]
15. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
[TBL] [Abstract][Full Text] [Related]
16. [Adjuvant treatment of prostatic carcinoma after primary therapy. The "Early Prostate Cancer" Program].
Mansueto G; Longo F
Recenti Prog Med; 2002 Mar; 93(3):175-8. PubMed ID: 11942169
[No Abstract] [Full Text] [Related]
17. A dramatic, objective antiandrogen withdrawal response: case report and review of the literature.
Lau YK; Chadha MK; Litwin A; Trump DL
J Hematol Oncol; 2008 Nov; 1():21. PubMed ID: 18986533
[TBL] [Abstract][Full Text] [Related]
18. Gynecomastia and breast pain induced by adjuvant therapy with bicalutamide after radical prostatectomy in patients with prostate cancer: the role of tamoxifen and radiotherapy.
Di Lorenzo G; Perdonà S; De Placido S; D'Armiento M; Gallo A; Damiano R; Pingitore D; Gallo L; De Sio M; Autorino R
J Urol; 2005 Dec; 174(6):2197-203. PubMed ID: 16280763
[TBL] [Abstract][Full Text] [Related]
19. [Monotherapy with antiandrogens for prostatic cancer].
Sander S
Tidsskr Nor Laegeforen; 1999 Apr; 119(10):1451-3. PubMed ID: 10354754
[TBL] [Abstract][Full Text] [Related]
20. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]